PTSD Trial, Recruiting NCT07079839 Sponsor: The University of Texas Health Science Center, Houston Condition: PTSD
Back to Ptsd

PTSD Trial, Recruiting

NCT07079839
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are right-handed
  • People who have normal vision, or vision that is fully corrected with glasses or contact lenses, and a normal sense of smell
  • People who are between 18 and 50 years old
  • People who pass a safety screening checklist for a brain stimulation procedure called tACS (for example, no serious head injury history — confirm with trial site for the full list)
  • For patients: People who have been diagnosed with PTSD
  • For patients who take psychiatric medications: People whose medication doses have been stable for at least the past 2 months
  • People who use substances occasionally, or patients with mild substance use disorder, who are able to stop use at least 48 hours before the experiment

Who may not be able to join:

  • People who have been diagnosed with a major medical illness (such as cancer, metabolic conditions, heart disease, or inflammatory disorders) or a neurological condition (such as epilepsy/seizures, stroke, or Parkinson's disease)
  • For patients: People who have another major mental health diagnosis at the same time — though depression, anxiety, and mild substance use disorder are generally allowed given how commonly they occur alongside PTSD (confirm with trial site)
  • For healthy volunteers (non-patients): People who have ever been diagnosed with a DSM-5 mental health disorder, or who are currently taking any psychiatric medications
  • People who are in severe psychiatric crisis, including anyone who is actively having thoughts of harming themselves or others, or whose behaviour poses an immediate danger
  • People who have had a head injury that caused them to lose consciousness for more than 5 minutes
  • People who regularly drink 3 or more alcoholic drinks per day
  • People who are not able to stop using substances (including alcohol, nicotine, cannabis, amphetamines, narcotics, solvents, cocaine, hallucinogens, tranquilisers, barbiturates, or similar) or sleep medications for 48 hours before the scan
  • People who take certain blood pressure medications called calcium channel blockers (such as verapamil or nifedipine) or alpha-blockers (such as prazosin or terazosin) and are not able to pause those medications for 48 hours before scanning
  • People who do not pass a urine drug screening test conducted before participation
  • People who are pregnant, as confirmed by a urine test — the safety of MRI scanning for unborn babies has not been fully established
  • People who have any electrically, magnetically, or mechanically activated implanted devices (such as a cardiac pacemaker), because the MRI equipment may interfere with how those devices work

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Wen Li, PhD, The University of Texas Health Science Center, Houston

Phone: (713) 486-2700

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
3 July 2025
Est. completion
1 July 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in neural oscillatory activity as assessed by electroencephalogram (EEG) alpha power change; Change in cortical activity as assessed by functional magnetic resonance imaging (fMRI) blood-oxygen-level-dependent (BOLD) signal change

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov